KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $370.1 million.

  • Supernus Pharmaceuticals' Total Liabilities rose 1029.23% to $370.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.1 million, marking a year-over-year increase of 1029.23%. This contributed to the annual value of $332.3 million for FY2024, which is 668.72% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Total Liabilities is $370.1 million, which was up 1029.23% from $318.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Total Liabilities high stood at $879.7 million for Q1 2023, and its period low was $316.6 million during Q1 2025.
  • For the 5-year period, Supernus Pharmaceuticals' Total Liabilities averaged around $572.0 million, with its median value being $374.9 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 3061.95% in 2021, then tumbled by 5737.84% in 2024.
  • Supernus Pharmaceuticals' Total Liabilities (Quarter) stood at $873.3 million in 2021, then fell by 6.53% to $816.3 million in 2022, then tumbled by 56.37% to $356.2 million in 2023, then dropped by 6.69% to $332.3 million in 2024, then grew by 11.36% to $370.1 million in 2025.
  • Its Total Liabilities stands at $370.1 million for Q3 2025, versus $318.5 million for Q2 2025 and $316.6 million for Q1 2025.